Australia Hereditary Cancer Testing Market to 2032

Overview

The Australia Hereditary Cancer Testing Market is expected to reach a 154.60 USD Million by 2032 and is projected to grow at a CAGR of 21.62% from 2025 to 2032.

Revenue, 2024 (USD Million)
55.95
Forecast, 2032 (USD Million)
154.60
CAGR, 2024 - 2032
21.62%
Report Coverage
Australia

Australia Hereditary Cancer Testing Market 2018-2032 USD Million

Australia Hereditary Cancer Testing Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 55.95 USD Million
  • Projected Market Size (2032): 154.60 USD Million
  • CAGR (2025-2032): 21.62%

Key Findings of Australia Hereditary Cancer Testing Market

  • The Australia Hereditary Cancer Testing Market was valued at 55.95 USD Million in 2024.
  • The Australia Hereditary Cancer Testing Market is likely to grow at a CAGR of 21.62% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Direct Tender in Distribution Channel Segment accounted for the largest share of the market with a revenue of 38.84 USD Million
  • The fastest growing segment Hospitals in End Users Segment grew Fastest with a CAGR of 22.45% during the forecast period from 2024 to 2032.

Australia Hereditary Cancer Testing Market Scope

Australia Hereditary Cancer Testing Market Segmentation & Scope
Diagnosis
  • Lab Tests
  • Imagining
  • Biopsy
Test
  • Single Site Genetic Test
  • Multi Panel Test
Disease
  • Multiple Endocrine Neoplasias (MEN) Syndrome
  • Von Hippel-Lindau Disease
  • Li-Fraumeni Syndrome
  • Familial Adenomatous Polyposis (FAP)
  • Hereditary Leukemia and Hematologic Malignancies Syndrome
  • Lynch Syndrome
  • Cowden Syndrome
  • Hereditary Breast & Ovarian Cancer Syndrome
Technology
  • Microarray
  • Sequencing
  • Polymerase Chain Reaction (PCR)
Distribution Channel
  • Retail Sales
  • Direct Tender
End Users
  • Others
  • Laboratories
  • Radiology Centres
  • Diagnostics Centers
  • Clinics
  • Hospitals

Australia Hereditary Cancer Testing Market Data Coverage Insights

Study Period 2024-2032
Base Year 2020
Unit Revenue in USD Million
Market Value in 2024 55.95 USD Million
Market Value in 2032 154.60 USD Million
CAGR (2025-2032) 21.62%
Historic Data 2016-2023
Market Segments Covered Diagnosis,Test,Disease,Technology,Distribution Channel,End Users

Regional Insights:

  • Leading Market (2024-2032): Australia, leading in terms of revenue 55.95 USD Million in 2024
    • Key Country: Australia, leading in terms of revenue with value of 55.95 USD Million in 2024.

Segments and Scope

  • Australia Hereditary Cancer Testing Market to 2032, By Diagnosis
    • Biopsy is the largest segment in Australia Hereditary Cancer Testing Market to 2032 with a revenue of 25.07 USD Million in the year 2024.
    • Biopsy is the Fastest growing segment in Australia Hereditary Cancer Testing Market to 2032 with a Growth rate of 21.97 % in forecast period 2025-2032.
  • Australia Hereditary Cancer Testing Market to 2032, By Test
    • Multi Panel Test is the largest segment in Australia Hereditary Cancer Testing Market to 2032 with a revenue of 37.06 USD Million in the year 2024.
    • Multi Panel Test is the Fastest growing segment in Australia Hereditary Cancer Testing Market to 2032 with a Growth rate of 22.01 % in forecast period 2025-2032.
  • Australia Hereditary Cancer Testing Market to 2032, By Disease
    • Hereditary Breast & Ovarian Cancer Syndrome is the largest segment in Australia Hereditary Cancer Testing Market to 2032 with a revenue of 33.05 USD Million in the year 2024.
    • Hereditary Breast & Ovarian Cancer Syndrome is the Fastest growing segment in Australia Hereditary Cancer Testing Market to 2032 with a Growth rate of 22.21 % in forecast period 2025-2032.
  • Australia Hereditary Cancer Testing Market to 2032, By Technology
    • Polymerase Chain Reaction (PCR) is the largest segment in Australia Hereditary Cancer Testing Market to 2032 with a revenue of 36.54 USD Million in the year 2024.
    • Polymerase Chain Reaction (PCR) is the Fastest growing segment in Australia Hereditary Cancer Testing Market to 2032 with a Growth rate of 22.09 % in forecast period 2025-2032.
  • Australia Hereditary Cancer Testing Market to 2032, By Distribution Channel
    • Direct Tender is the largest segment in Australia Hereditary Cancer Testing Market to 2032 with a revenue of 38.84 USD Million in the year 2024.
    • Direct Tender is the Fastest growing segment in Australia Hereditary Cancer Testing Market to 2032 with a Growth rate of 21.79 % in forecast period 2025-2032.
  • Australia Hereditary Cancer Testing Market to 2032, By End Users
    • Hospitals is the largest segment in Australia Hereditary Cancer Testing Market to 2032 with a revenue of 22.15 USD Million in the year 2024.
    • Hospitals is the Fastest growing segment in Australia Hereditary Cancer Testing Market to 2032 with a Growth rate of 22.45 % in forecast period 2025-2032.

Australia Hereditary Cancer Testing Market Company Share Analysis

 
Company Name Company Share Analysis
PerkinElmer Inc.
illumina, inc.
Abbott
Eurofins Scientific
LifeLabs Genetics
Australia Hereditary Cancer Testing Market Company Share Analysis

Australia Hereditary Cancer Testing Market Geographical Sales Distribution, 2018-2032 USD Million

Australia Hereditary Cancer Testing Market Geographical Sales Distribution, 2018-2032 USD Million

Australia Hereditary Cancer Testing Market Company Profiling

Australia Hereditary Cancer Testing Market Company Profiling
Frequently Asked Questions
The Australia Hereditary Cancer Testing Market is segmented based on Segmentation Diagnosis,Test,Disease,Technology,Distribution Channel,End Users.
Australia Hereditary Cancer Testing Market was valued at USD 55.95(Revenue in USD Million) in 2020.
Australia Hereditary Cancer Testing Market is projected to grow at a CAGR of 21.62% during the forecast period of 2024 to 2032.
The Direct Tender segment is expected to dominate the Australia Hereditary Cancer Testing Market, holding a largest market share of 38.84 USD Million in 2024

Australia Hereditary Cancer Testing Market Scope

Australia Hereditary Cancer Testing Market Segmentation & Scope
Diagnosis
  • Lab Tests
  • Imagining
  • Biopsy
Test
  • Single Site Genetic Test
  • Multi Panel Test
Disease
  • Multiple Endocrine Neoplasias (MEN) Syndrome
  • Von Hippel-Lindau Disease
  • Li-Fraumeni Syndrome
  • Familial Adenomatous Polyposis (FAP)
  • Hereditary Leukemia and Hematologic Malignancies Syndrome
  • Lynch Syndrome
  • Cowden Syndrome
  • Hereditary Breast & Ovarian Cancer Syndrome
Technology
  • Microarray
  • Sequencing
  • Polymerase Chain Reaction (PCR)
Distribution Channel
  • Retail Sales
  • Direct Tender
End Users
  • Others
  • Laboratories
  • Radiology Centres
  • Diagnostics Centers
  • Clinics
  • Hospitals
Frequently Asked Questions
The Australia Hereditary Cancer Testing Market is segmented based on Segmentation Diagnosis,Test,Disease,Technology,Distribution Channel,End Users.
Australia Hereditary Cancer Testing Market was valued at USD 55.95(Revenue in USD Million) in 2020.
Australia Hereditary Cancer Testing Market is projected to grow at a CAGR of 21.62% during the forecast period of 2024 to 2032.
The estimated market value of the Australia Hereditary Cancer Testing Market for final year is USD 154.60 (USD Million).

Australia Hereditary Cancer Testing Market Company Profiling

Australia Hereditary Cancer Testing Market Company Profiling
Frequently Asked Questions
The Australia Hereditary Cancer Testing Market is segmented based on Segmentation Diagnosis,Test,Disease,Technology,Distribution Channel,End Users.
Australia Hereditary Cancer Testing Market was valued at USD 55.95(Revenue in USD Million) in 2020.
Australia Hereditary Cancer Testing Market is projected to grow at a CAGR of 21.62% during the forecast period of 2024 to 2032.
The estimated market value of the Australia Hereditary Cancer Testing Market for final year is USD 154.60 (USD Million).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.